Compare JOUT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOUT | IMMP |
|---|---|---|
| Founded | 1970 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.6M | 426.9M |
| IPO Year | N/A | N/A |
| Metric | JOUT | IMMP |
|---|---|---|
| Price | $44.87 | $2.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 50.4K | ★ 287.8K |
| Earning Date | 02-02-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $592,415,000.00 | $3,306,742.00 |
| Revenue This Year | $8.66 | $292.48 |
| Revenue Next Year | $5.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.28 |
| 52 Week Low | $21.33 | $1.32 |
| 52 Week High | $48.50 | $3.53 |
| Indicator | JOUT | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 59.60 | 58.03 |
| Support Level | $42.37 | $2.91 |
| Resistance Level | $45.93 | $3.16 |
| Average True Range (ATR) | 1.45 | 0.15 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 86.05 | 41.67 |
Johnson Outdoors Inc is a manufacturer and marketer of branded seasonal, outdoor recreation products used for fishing from a boat, diving, paddling, hiking and camping. The company has four operating segment: Fishing, Camping, Watercraft Recreation, and Diving. It generates maximum revenue from the Fishing segment which produces and markets products under different brands such as Minn Kota electric motors for quiet trolling or primary propulsion, marine battery chargers and shallow water anchors; Humminbird sonar and GPS equipment for fish finding, navigation and marine cartography; and Cannon downriggers for controlled-depth fishing. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe, Canada, and other regions.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.